Information:
Error:
ID
14003
Description
Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy; ODM derived from: https://clinicaltrials.gov/show/NCT01819558
Link
https://clinicaltrials.gov/show/NCT01819558
Keywords
Versions (1)
- 3/21/16 3/21/16 -
Uploaded on
March 21, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Acute Myeloid Leukemia NCT01819558
Eligibility Acute Myeloid Leukemia NCT01819558
- StudyEvent: Eligibility
Similar models
Eligibility Acute Myeloid Leukemia NCT01819558
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Age
Item
Patients older than 18 and younger than 65 years.
boolean
C0001779 (UMLS CUI [1])
Karnofsky Performance Status
Item
Karnofsky Performance Status ≥ 70 %
boolean
C0206065 (UMLS CUI [1])
Allogeneic Hematopoietic Stem Cell Transplantation
Item
Patients with acute or chronic myeloid leukemia, or myelodysplastic syndrome, who underwent allogeneic stem cell transplantation from hla-identical donor (related or unrelated) after reduced-intensity conditioning regimen.
boolean
C1705576 (UMLS CUI [1])
Complete remission
Item
Patients in morphologic complete remission at the time of transplantation.
boolean
C0677874 (UMLS CUI [1])
WT1 gene
Item
Wt1 expression detectable on tumor cells.
boolean
C0694898 (UMLS CUI [1])
Life Expectancy
Item
Expected life duration more than 6 months.
boolean
C0023671 (UMLS CUI [1])
Creatinine clearance
Item
Creatinine clearance ≥ 50 ml/min
boolean
C0812399 (UMLS CUI [1])
Bilirubinemia
Item
Bilirubinemia < 1.5n and asat < 2.5n
boolean
C0020433 (UMLS CUI [1])
Negative pregnancy test and effective contraception
Item
Women of childbearing age: negative pregnancy test and effective contraception for at least 30 days before vaccinal immunotherapy (the same contraceptive method must be continued at least 2 months after the last vaccine infusion).
boolean
C0427780 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
C0700589 (UMLS CUI [2])
Social Security
Item
Membership of a social security scheme or beneficiary of such a regime.
boolean
C0037435 (UMLS CUI [1])
Informed Consent
Item
Signed inform consent
boolean
C0021430 (UMLS CUI [1])
Graft-vs-Host Disease
Item
Patients with severe and uncontrolled affections, especially active graft-versus-host disease requiring steroid treatment (>0.3 mg/kg/j) and/or mycophenolate mofetil.
boolean
C0018133 (UMLS CUI [1])
Pregnant or lactating women
Item
Pregnant or lactating women
boolean
C3242212 (UMLS CUI [1])
HIV positive
Item
HIV Seropositivity
boolean
C0019699 (UMLS CUI [1])
Autoimmune Diseases
Item
Autoimmune disease (lupus, multiple sclerosis, chrone disease)
boolean
C0004364 (UMLS CUI [1])
Allergic disposition
Item
Previous history of allergic state which could be potentially compound by a component of the vaccinal immunotherapy.
boolean
C3539909 (UMLS CUI [1])
Experimental treatment
Item
Patients who received (or are planned to receive) another experimental treatment within 30 days following the first infusion of the experimental drug of this protocol.
boolean
C0087111 (UMLS CUI [1,1])
C0015320 (UMLS CUI [1,2])
C0015320 (UMLS CUI [1,2])
Malignant Neoplasms
Item
Previous history of another cancer, except if considered as probably cured by the investigator.
boolean
C0006826 (UMLS CUI [1])
Gardianship
Item
Patients deprived of liberty, or under guardianship.
boolean
C0870627 (UMLS CUI [1])